Login to Your Account

NewCo News: Cyrenaic Targets Untreated Schizophrenia Symptoms

By Marie Powers

Wednesday, March 16, 2011
Cyrenaic Pharmaceuticals Inc. is a little company with big dreams. The privately held biotech, based in Princeton, N.J., is focused on the development of CYR-101, an antipsychotic in clinical development for the treatment of schizophrenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription